Kardium, a medical technology company based in Vancouver, British Columbia, has raised $250 million in an oversubscribed financing round to support the commercial launch of its pulsed field ablation (PFA) system, Globe. The round included new investors such as Janus Henderson Investors, Qatar Investment Authority, MMCAP, Piper Heartland Healthcare Capital, Eventide Asset Management, and Eckuity Capital, along with existing backers like T. Rowe Price and Durable Capital Partners. An anonymous leading strategic investor also participated through an equity investment. The funding will help Kardium pursue regulatory approvals, expand manufacturing and clinical support teams, and conduct further clinical research for the Globe system’s additional applications.
Kardium’s Globe system features a 122-electrode array catheter with advanced software that enables high-definition mapping, rapid pulmonary vein isolation, and ablation in any part of the atrium, all in one device. The system also uses proprietary Contact maps to ensure precise therapy delivery, requiring an average of just 1.2 applications per vein. Kevin Chaplin, CEO of Kardium, stated, “This funding enables us to move ahead with the commercial launch of the Globe system by expanding our manufacturing capabilities and building a strong commercial team. Everyone at Kardium is energized by the opportunity to bring the Globe system to market and help improve the lives of millions of patients worldwide suffering from atrial fibrillation.”
